Peer Review History
| Original SubmissionMarch 2, 2025 |
|---|
|
Dear Dr. Solli, Please submit your revised manuscript by Jun 21 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Nishant Premnath Jaiswal, MBBS, PhD Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. We note that you have contradictory statements about the literature search in your manuscript. Please can you remove the list of languages the studies reported are in as this suggests that a language restriction was imposed. 3. As required by our policy on Data Availability, please ensure your manuscript or supplementary information includes the following: A numbered table of all studies identified in the literature search, including those that were excluded from the analyses. For every excluded study, the table should list the reason(s) for exclusion. If any of the included studies are unpublished, include a link (URL) to the primary source or detailed information about how the content can be accessed. A table of all data extracted from the primary research sources for the systematic review and/or meta-analysis. The table must include the following information for each study: Name of data extractors and date of data extraction Confirmation that the study was eligible to be included in the review. All data extracted from each study for the reported systematic review and/or meta-analysis that would be needed to replicate your analyses. If data or supporting information were obtained from another source (e.g. correspondence with the author of the original research article), please provide the source of data and dates on which the data/information were obtained by your research group. If applicable for your analysis, a table showing the completed risk of bias and quality/certainty assessments for each study or outcome. Please ensure this is provided for each domain or parameter assessed. For example, if you used the Cochrane risk-of-bias tool for randomized trials, provide answers to each of the signalling questions for each study. If you used GRADE to assess certainty of evidence, provide judgements about each of the quality of evidence factor. This should be provided for each outcome. An explanation of how missing data were handled. This information can be included in the main text, supplementary information, or relevant data repository. Please note that providing these underlying data is a requirement for publication in this journal, and if these data are not provided your manuscript might be rejected. 4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Abstract: Please clarify the statement that the effect on medications was uncertain. Methods did not describe a search for effects on any medication. Page 10 of the manuscript describes monitoring use of "fall-risk increasing drugs”. It may help to mention this in the abstract so readers know what type of medications were measured/reported. The statement, “CDS interventions may reduce fall injury rate in older adults aged between 65 and 80 years (RaR 0.80; 95% CI 0.59, 1.09)” does not seem accurate because the confidence interval crosses the 1.0 value. Please consider restating this If I understand the data correctly, it may be more accurate to change the last sentence of the Abstract to: “but the evidence on fall injury rate in community-dwelling patients aged 80 years or older was very uncertain.” In other words, CDS use worked well in hospitals and residential care, but the effect was not statistically significant in community dwelling patients. This is such an important observation that it needs to be clear here and in the Conclusion of the Abstract on Page 3. Manuscript (MS) Please check grammar throughout the MS. For example, Page 4, Introduction line 2 “leading” should be “leads”. This is an important, well-done study, potentially affecting important clinical and health economic outcomes. Grammatical errors distract from its credibility and potential clinical use. I do not have time to address every grammatical error. This needs review by a good editor. Reviewer #2: This systematic review and meta-analysis is an important contribution to the literature on fall prevention in older adults using CDS interventions. The methodology is rigorous, and the conclusions are generally well-supported by the evidence. Strengths include the comprehensive search, transparent methods, proper use of meta-analytic techniques, subgroup analyses, and the application of GRADE. Minor points for improvement: Discussion clarity: Some explanations regarding the difference between fall rate and fall risk outcomes could be streamlined to enhance reader understanding. Graphical presentation: Figures could be slightly improved to enhance readability (e.g., legends and risk of bias charts could be made larger for clarity). No ethical concerns were identified. No concerns regarding plagiarism, redundant publication, or data fabrication were noted. Recommendation: Minor revision (language polishing in Discussion and minor graphical improvements). ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Laura Bolton, PhD Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org |
| Revision 1 |
|
Dear Dr. Solli, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 22 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Nishant Premnath Jaiswal, MBBS, PhD Academic Editor PLOS ONE Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: (No Response) Reviewer #3: All comments have been addressed Reviewer #4: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: Partly Reviewer #4: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: No Reviewer #3: Yes Reviewer #4: Yes ********** Reviewer #2: This manuscript addresses an important and timely topic: the effectiveness of Clinical Decision Support (CDS) systems in fall prevention among older adults. The systematic review and meta-analysis are well designed, and the authors follow rigorous methods aligned with PRISMA and GRADE guidelines. However, several aspects require major attention before the manuscript can be considered for publication... Language and Grammar (Essential Revision): The manuscript still contains numerous grammatical and syntactical issues that reduce clarity and weaken its impact. A professional English language editing is essential, especially in the Introduction and Discussion sections. For example: Line 93: “Falls can cause significant health loss that leads to more complex care requirements” → awkward phrasing. Line 92: “Falls are a major cause of morbidity and mortality…” → avoid redundancy by rephrasing the following lines more concisely. GRADE Interpretation (Overstatement): The authors frequently describe outcomes with low or very low certainty as "may improve" or "likely reduce." While this aligns with GRADE semantics, the consistent use of optimistic phrasing throughout the abstract and conclusion may mislead readers about the strength of evidence. I strongly recommend a more cautious tone, especially for: Medication outcomes: classified as “low certainty” but still interpreted positively. Fall injury in those 65–80 years: RaR 0.80 with CI crossing 1.00 should be clearly described as statistically non-significant. Methodological Transparency: The authors claim no language restriction, but earlier versions included a list of included languages. Ensure this inconsistency is corrected in both the Methods and Appendices. Risk of bias assessments are now available in S7 Table, but summary RoB graphs in the main text are difficult to interpret (small font, unclear legends). Please improve readability and ensure consistency between main text and supplements. Data Completeness (Minor): The explanation for handling missing data is too brief. Please detail the imputation procedures used and specify how often author contact led to data retrieval. Figures and Tables: Figure readability is still suboptimal despite the revisions. Font sizes and labeling in forest plots and risk-of-bias visuals should be increased for clarity, especially for print versions. Minor Points: Use consistent terminology: sometimes "CDS systems" is used redundantly (the "S" already stands for "system"). Add a visual summary table of GRADE certainty per outcome (possibly alongside S9 Table) in the main manuscript for quick reference. Discuss potential implementation barriers to CDS in LMIC settings – currently the review is biased toward high-income contexts. Overall Recommendation: Minor Revision – Language and Presentation Improvements Required. Reviewer #3: Thank you for acknowledging the reviewers comment and your revisions. The paper looks better, but I still have a number of issues/questions: Pg. 5 ln 118 - Suggest changing to "Generally, the use of CDS by healthcare ...." Pg 5 ln 121 - suggest changing to "patients [32], medication outcomes in older adults [33,34], and adults in general. Pg 6 ln 134 - suggest changing to "This systematic review aimed to evaluate the effects of CDS for...." Pg 8 ln 172 - since your inclusion criteria included restrictions on the type of studies for inclusion in the review, please clarify why you did not include restrictions on the study design within your search strategy? Pg 10 ln 208 - Why did you include studies which did not specify one of your required outcomes? Pg 14 ln 301 - what do you mean by the phrase "to a median (min-max) of 1 433 (312-46245) patient participants? Pg 24 ln 460 - your interpretation of the impact of CDS on falls in hospital/residential care, although was significant, needs to include the considerable heterogenity present. Pg 24 ln 466-478 - your interpretation of the sub group analysis I feel is inaccurate and likely do not reduce the rate of falls. Pg 28 ln 572-574 - your results do not reflect that CDS does not reduce falls in pts >80 Pg 33 - Strengths and limitations section - please expand more on limitations of the review Pg 34. Reviewer #4: Reviewer comments Thank you for the opportunity to review this revised manuscript. I did not review the original version but have examined the responses to the previous reviewer comments and have reviewed the revised version anew from my perspective. I did not verify that all requests by the Academic Editor were addressed, but notice that the author did not add any information into the manuscript, as stated in their response, about any methods for author contact for missing outcome data. If they did perform author contact, the means (eg email first author) and frequency should be stated. Responses to reviewers 1 and 2. The comments to the previous reviewer comments are mostly addressed, though as indicated below more work should be done to define the author’s GRADE approach. The review is well done and will be improved in my opinion with some minor changes and consideration of one major comment on GRADE. My comments: Minor comments: Abstract: i) please note the search date(s), ii) if space permits it would be excellent to provide a brief overview of the types of CDS interventions used most, iii) please see below for some suggestions and questions about the GRADE approach which may influence the reporting of results in the abstract Introduction: stating that “interventions to prevent falls” are cost-effective and effective in falls and fall injuries could be more specific especially since not all interventions have been shown successful and the authors are arguing for a review of CDS interventions. Possibly “a variety of interventions aimed at older adults” or such would help. Materials and methods: 1. Was the protocol only ever “drafted”? even if there were changes post hoc the protocol should have been in some form of final version before starting the review. 2. Spell out PRISMA at first use 3. Selection process: please add details about who conducted full text review, and confirm whether consensus was required at title/abstract stage or just full text. 4. Data collection process: using verification for only 5 of 24 papers should be noted in the discussion as a limitation of the review (possibility for errors). Duplicate extraction or verification of all data is a standard for systematic reviews. This is particularly concerning if only one person chose which outcome data to use when studies reported on multiple outcomes. 5. Study risk of bias: please confirm if “the main outcome results” means the result data used for each outcome of interest to the review, or otherwise. 6. Synthesis methods: please add a section on unit of analysis issues, i.e. what was done to account for effects of clustering in cluster RCTs? Was the authors’ result adjusted for clustering used for analysis and, if not reported/performed, what was done? Results/conclusions: 1. it would be of interest to comment on how many studies had eligibility criteria related to increased risk for falls (e.g. previous fallers, 1+ risk factor etc), and to state whether the findings overall are most applicable to populations at increased risk (this may vary by outcome to some degree), 2. it is hard to know whether the findings for the fall risk outcome may be most applicable to certain settings or ages; can the authors comment on whether the 10 studies appeared to capture both settings and ages fairly well? For example, if the large majority of the participants in the analysis came from studies undertaken in residential/acute care there could be some concerns about directness to the entire population of interest (eg rating down for indirectness may apply) or some way to clarify this observation for the reader, 3. likewise with setting and age groups for fall rates is there any indication that the studies in residential/acute care also enrolled older people to help know whether findings could be most applicable to both setting and age combined?, 4. conversion of ORs to absolute risk difference (for falls risk) should first convert the OR to a RR (see appendix 3 in https://www.bmj.com/content/389/bmj-2024-081904), 5. the authors should speak to their reason for use of a separate study (ref 88) for control event rates (rather than the studies themselves) and describe this study in some detail, 6. in figure 2 there are some “FU” and “follow-up” so this could be made consistent; further the authors should be able to put something into the figure for the medication outcome findings for the Blalock study, even if just a narrative statement by the authors about the direction of effect, 7. for mortality and hospitalizations the reversion to relying on statistical significance goes against what was done for other outcomes; perhaps the authors comment about any directions of effect, speak to the small sample sizes for these rare outcomes and point again to where folks can find the results if they want. Line 561-2: would suggest deleting this sentence since the authors did not assess the magnitude of effects in their review Major comment: GRADE does not asses the certainty of the point estimate per se but it’s relation to the “target” of certainty which should be defined in the methods section (see GRADE 34 guidance and J Clin Epidemiol. 2017 Jul:87:4-13. doi: 10.1016/j.jclinepi.2017.05.006 and BMJ. 2025 Apr 29:389:e081904. doi: 10.1136/bmj-2024-081904). For the provider outcomes, the target would need to be a direction of effect only since the analysis did not assess magnitude. For the patient outcomes, this could have been the null (direction of effect) or some form of a minimally important difference (even if approximate), especially to help determine whether findings are “little to no difference” or “an affect”. It appears the authors just used direction of effect and if so this should be mentioned and the findings should be stated in this light. It is confusing what the authors have done for this since there is no statement in the methods and for falls risk (OR 0.93, 21 fewer fallers per 1000) they state little to no effect in the results (implying 21 fewer is below some threshold of an MID) but a slight reduction in the abstract and discussion. The choice of the target can change the GRADE ratings for all domains but in particular inconsistency and imprecision. For the provider outcomes, rating a conclusion of direction of effect where all studies showed the same direction would suggest against rating down for inconsistency; the size of effect doesn’t matter for this target. With some of the effects not being statistically significant/precise for the direction there could be concern over imprecision but it may not be serious. For direction of effect for adherence, I would think low certainty overall seems appropriate with the text indicating rating down twice for ROB. The same applies for medication outcomes, unless the authors want to have a third category of No direction which a couple of the findings indicate (e.g. Blum & Lightbody) and where some inconsistency in direction could be noted. If the authors really think low certainty for the direction is appropriate (vs moderate with just serious ROB) they could consider rating down twice for ROB or possibly once for ROB and once for imprecision (as above) or inconsistency (noting really that a direction was not shown in a couple of cases). For the falls risk outcome, if the authors are rating certainty in direction of effect, then not rating down for imprecision makes sense (assuming they wouldn’t be too strict on the upper limit of the 95% CI crossing the null slightly) and they would conclude there is an effect (possibly mentioning that it may not be important), but if they want to say there is “little to no” difference (implying use of an MID and that the point estimate is below this) then they likely should state what the MID was and make sure the entire 95% CI does not contain this value or else also rate down for imprecision. For the falls rate outcomes, if using a direction of effect the authors should note this in their conclusions whereas if they think the magnitude is at least as large as some small but important effect they may also rate down for either inconsistency (since ~30% of the weight in the analysis showed effects below what might be considered an MID) or for imprecision if the lower limit of the 95%CI (81 fewer falls) does not surpass their MID. In summary, having a clear statement about what the authors were rating their certainty in (e.g. null/direction of effect) would be good as well as re-considering their assessments for the provider outcomes in light of this (not rating down for inconsistency). If using the direction of effect their falls risk findings should likely be “an effect”, with a comment that the effects may be small. If MIDs were applied these should be stated with the above considerations added. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #3: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Dear Dr. Solli, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Nov 24 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
We look forward to receiving your revised manuscript. Kind regards, Sascha Köpke Academic Editor PLOS ONE Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed Reviewer #4: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** Reviewer #2: This manuscript addresses a highly relevant topic, considering the growing prevalence of falls among older adults and the urgent need for effective interventions. The systematic review and meta-analysis presented demonstrate methodological rigor, including a comprehensive search strategy across multiple databases, application of the GRADE approach, and appropriate use of meta-analytic techniques. Strengths Comprehensive and transparent search strategy. Clearly defined inclusion criteria, encompassing different study designs. Robust synthesis of the data, including both meta-analyses and risk of bias assessment. Discussion aligned with the presented evidence, highlighting differences between settings (hospital/residential care versus community). Suggestions for Improvement Clarity on outcomes: The explanation of the difference between “fall rate” and “fall risk” could be made more concise and accompanied by practical examples to improve readability for a broader audience. English language polishing: Although the manuscript has been revised, some sentences could be more fluent and precise. A professional language editing service is recommended. Graphical presentation: Figures and tables have been improved, but further adjustments could increase readability, such as standardizing font size and enlarging legends, especially for risk-of-bias charts. Practical conclusions: It would strengthen the paper to explicitly emphasize in the discussion the clinical and implementation implications across different settings (primary care versus hospital/residential), to enhance the translation of findings into practice. Overall, this is a technically sound study with data that support its conclusions. It represents a valuable contribution to the literature on fall prevention in older adults. I recommend acceptance after minor revisions, mainly focusing on clarity of writing, conceptual distinction between outcomes, and minor graphical improvements. Reviewer #3: Thank you for resubmitting your revised manuscript, and you have taken into consideration the reviewers feedback. I do have some ongoing feedback /questions which is included in the document which is around: 1. The final number of included studies reported in the manuscript is different to that reported in the PRISMA diagram - please clarify the actual number. 2. Your eligibility criteria is confusing - your report only including studies based in healthcare settings, yet you included community dwelling studies? 3. I do not agree with all your interpretations about the results obtained - you indicate that CDS may reduce fall rate across all age groups and settings, yet this is not supported by your results. Please re-evaluate this. Reviewer #4: Good revision. Only 2 minor comments for revision. 1. for the GRADE rating of injurious falls in the 80+ age category, there should only be one level rated down for imprecision since the effect shows harm (magnitude not relevant) with slight imprecision (0.99 lower CI limit). This won't change the overall GRADE but will add accuracy. 2. in the discussion, the beginning sentence of the patient outcomes section uses one of the 4 estimates for falls rates without a reason. Perhaps just state that the intervention may reduce fall risk (14 fewer) and fall rates (range 20-188 fewer), since you later discuss the differences across subgroups. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #3: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org
|
| Revision 3 |
|
Effectiveness of clinical decision support in fall prevention among older adults: a systematic review and meta-analysis PONE-D-25-10237R3 Dear Dr. Solli, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Sascha Köpke Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-25-10237R3 PLOS One Dear Dr. Solli, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Sascha Köpke Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .